INSPIRE consortium receives UK MHRA approval for study
Liverpool and London, UK – November 3 2015: The INSPIRE consortium, led by Videregen Ltd, has received approval from the MHRA1 to start a UK clinical trial with its tissue engineered replacement trachea. The trial, which is expected to start in the first half of 2016, will focus on severe structural airway disease (SSAD), a potentially life-threatening condition believed to affect 19,000 people in Europe and the US. Along with Videregen as commercial partner, the consortium includes the Cell Therapy Catapult, University College London (UCL), NHS Blood and Transplant in Speke and the Royal Free London NHS Foundation Trust.
The Phase I trial, which will recruit four patients with SSAD, is to assess the safety and initial efficacy of the product. While replacement trachea technologies have been tested previously in compassionate use cases, this is the first formal clinical trial of a tissue engineered autologous stem cell trachea replacement. The INSPIRE project started in 2014, and has £1.9m of funding from Innovate UK.
SSAD is associated with significant airway obstruction leading to high levels of morbidity and a 50% mortality rate if not treated successfully. Current treatment involves surgery which has a high incidence of failure and lack of efficacy. In contrast, this tracheal replacement approach, which involves repopulating an acellular trachea ‘scaffold’ with the patient’s own stem cells, is designed to be a one-off curative treatment without the need for a lifetime of anti-rejection drugs thereafter.
The INSPIRE clinical trial will be led by Professors Martin Birchall and Mark Lowdell at UCL with the Cell Therapy Catapult as clinical trial sponsor and a provider of regulatory expertise. Videregen’s proprietary decellularisation technology, originally developed at Northwick Park Institute for Medical Research, is used by NHS Blood and Transplant to manufacture the trachea scaffold. The Centre for Cell, Gene and Tissue Therapy at the Royal Free London NHS Foundation Trust has developed the stem cell seeding processes so that the final product can be manufactured in its state-of-the-art facilities.
Speaking for the consortium, Dr Steve Bloor, CEO of Videregen, said, ‘Approval from the UK MHRA for this clinical trial is an important milestone for Videregen and the INSPIRE team, moving this transformative approach to airways disease one stage closer to market. The consortium approach, bringing together expertise from the Cell Therapy Catapult, clinician scientists at UCL, NHS Blood and Transplant and the Royal Free London NHS Foundation Trust, has enabled us to make good progress with this exciting project. Innovate UK’s funding was an important first step towards the trial, which is critical in transforming trachea replacement from occasional compassionate use to a treatment that could benefit thousands of patients. It also helps to expand the technology into other indications, and the consortium is grateful for Innovate UK’s continued support.’
1 Medicines & Healthcare products Regulatory Agency
Download PDF Version of Press Release – VDRGN-et-al-CTA-approval-02-11-15-FINAL.pdf
For more information, please contact:
Dr Steve Bloor, CEO +44 (0) 151 482 9350
Emma Palmer Foster, Strategic Communications Consultant +44 (0) 7880 787185
Cell Therapy Catapult
Neil Hunter/Michelle Boxall +44 (0) 208 943 4685
Harry Dayantis, Media Relations Manager +44 (0) 203 108 3844
Press Office on +44 (0)1923 367600
Royal Free London NHS Foundation Trust
Communications team via
firstname.lastname@example.org +44 (0)20 7472 6665/(0)20 7317 7740
Videregen is a clinical-stage regenerative medicine company using its proprietary stem cell-based technology platform to develop a range of personalised, non-immunogenic organ replacement products for orphan indications. Its lead programme is a tissue engineered trachea replacement, and its patented technology and know-how is also being applied to the development of other organ replacement products, including mucosal lining, small bowel and liver replacements. The platform technology, which uses decellularised organ scaffolds seeded with the patient’s own cells to create new organs, has the potential to generate cost-effective and curative therapies for a range of devastating diseases. Founded in 2011, Videregen is an SME based in Liverpool. Its investors include SPARK Impact, London Business Angels and others. For more information please go to www.videregen.com
About the Cell Therapy Catapult
The Cell Therapy Catapult was established in 2012 as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 100 employees focusing on cell and gene therapy technologies, we work with our partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. We offer leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. We aim to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. Regenerative medicine is one of the UK government’s eight great technologies that support UK science strengths and business capabilities. The Cell Therapy Catapult works with Innovate UK. For more information go to ct.catapult.org.uk or visit www.gov.uk/innovate-uk.